MACC1: A potential molecule associated with pancreatic cancer metastasis and chemoresistance

Oncology Letters

Volumn 4, Issue 4, 2012, Pages 783-791

  Wang, Gang ^a   Kang, Mu Xing ^a   Lu, Wen Jie ^a   Chen, Ying ^a   Zhang, Bo ^a   Wu, Yu Lian ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Chemoresistance; Epithelial mesenchymal transition; Metastasis; Metastasis associated in colon cancer 1

Indexed keywords

GEMCITABINE; SMALL INTERFERING RNA;

ADULT; ARTICLE; BLOOD ANALYSIS; CANCER CELL; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RESISTANCE; CANCER STAGING; CANCER THERAPY; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISTANT METASTASIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; METASTASIS ASSOCIATED IN COLON CANCER 1 GENE; ONCOGENE; PANCREAS CANCER; SIGNAL TRANSDUCTION;

EID: 84864698580     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.784     Document Type: Article

References (30)

1. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics. CA Cancer J Clin 60: 277-300, 2010.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
3. Pliarchopoulou K and Pectasides D: Pancreatic cancer: Current and future treatment strategies. Cancer Treat Rev 35: 431-436, 2009.
4. Maitra A and Hruban RH: Pancreatic cancer. Annu Rev Pathol 3: 157-188, 2008.
5. Shen J, Person MD, Zhu J, Abbruzzese JL and Li D: Protein expression profiles in pancreatic adenocarcinoma compared with normal pancreatic tissue and tissue affected by pancreatitis as detected by two-dimensional gel electrophoresis and mass spectrometry. Cancer Res 64: 9018-9026, 2004.
6. Stein U, Walther W, Arlt F, et al: MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis. Nat Med 15: 59-67, 2009.
7. Arlt F and Stein U: Colon cancer metastasis: MACC1 and Met as metastatic pacemakers. Int J Biochem Cell Biol 41: 2356-2359, 2009.
8. Shirahata A, Shinmura K, Kitamura Y, et al: MACC1 as a marker for advanced colorectal carcinoma. Anticancer Res 30: 2689-2692, 2010.
9. Shirahata A, Fan W, Sakuraba K, et al: MACC 1 as a marker for vascular invasive hepatocellular carcinoma. Anticancer Res 31: 777-780, 2011.
10. Chundong G, Uramoto H, Onitsuka T, et al: Molecular diagnosis of MACC1 status in lung adenocarcinoma by immunohistochemical analysis. Anticancer Res 31: 1141-1145, 2011.
11. Shimokawa H, Uramoto H, Onitsuka T, et al: Overexpression of MACC1 mRNA in lung adenocarcinoma is associated with postoperative recurrence. J Thorac Cardiovasc Surg 141: 895-898, 2011.
12. Shirahata A, Sakata M, Kitamura Y, et al: MACC 1 as a marker for peritoneal-disseminated gastric carcinoma. Anticancer Res 30: 3441-3444, 2010.
13. Sobin LH and Wittekind WC (eds): TNM Classification of Malignant Tumours (UICC). 6th edition. Wiley-Liss, New York, pp93-96, 2002.
14. Altman DG, Lausen B, Sauerbrei W and Schumacher M: Dangers of using 'optimal' cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 86: 829-835, 1994.
15. Arlt A, Gehrz A, Muerkoster S, et al: Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene 22: 3243-3251, 2003.
16. Qiu J, Huang P, Liu Q, et al: Identification of MACC1 as a novel prognostic marker in hepatocellular carcinoma. J Transl Med 9: 166, 2011.
17. Zhang R, Shi H, Chen Z, Wu Q, Ren F and Huang H: Effects of metastasis-associated in colon cancer 1 inhibition by small hairpin RNA on ovarian carcinoma OVCAR-3 cells. J Exp Clin Cancer Res 30: 83, 2011.
18. Shook D and Keller R: Mechanisms, mechanics and function of epithelial-mesenchymal transitions in early development. Mech Dev 120: 1351-1383, 2003.
19. Yang J and Weinberg RA: Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell 14: 818-829, 2008.
20. Shah AN, Summy JM, Zhang J, Park SI, Parikh NU and Gallick GE: Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann Surg Oncol 14: 3629-3637, 2007.
21. Wang Z, Li Y, Kong D, et al: Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res 69: 2400-2407, 2009.
22. Arumugam T, Ramachandran V, Fournier KF, et al: Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res 69: 5820-5828, 2009.
23. Bos JL: Ras oncogenes in human cancer: a review. Cancer Res 49: 4682-4689, 1989.
24. Calvo F, Agudo-Ibanez L and Crespo P: The Ras-ERK pathway: understanding site-specific signaling provides hope of new anti-tumor therapies. Bioessays 32: 412-421, 2010.
25. Deramaudt T and Rustgi AK: Mutant KRAS in the initiation of pancreatic cancer. Biochim Biophys Acta 1756: 97-101, 2005.
26. Rejiba S, Wack S, Aprahamian M and Hajri A: K-ras oncogene silencing strategy reduces tumor growth and enhances gemcitabine chemotherapy efficacy for pancreatic cancer treatment. Cancer Sci 98: 1128-1136, 2007.
27. Nishida K and Hirano T: The role of Gab family scaffolding adapter proteins in the signal transduction of cytokine and growth factor receptors. Cancer Sci 94: 1029-1033, 2003.
28. Gu H and Neel BG: The 'Gab' in signal transduction. Trends Cell Biol 13: 122-130, 2003.
29. Yart A, Laffargue M, Mayeux P, et al: A critical role for phosphoinositide 3-kinase upstream of Gab1 and SHP2 in the activation of ras and mitogen-activated protein kinases by epidermal growth factor. J Biol Chem 276: 8856-8864, 2001.
30. Cunnick JM, Meng S, Ren Y, et al: Regulation of the mitogen-activated protein kinase signaling pathway by SHP2. J Biol Chem 277: 9498-9504, 2002.